Allogene Therapeutics (ALLO) Earnings Date & Reports

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

ALLO is expected to report earnings to rise 2.29% to -28 cents per share on April 30

Allogene Therapeutics ALLO Stock Earnings Reports

Q1'25

Est.

$-0.29

Q4'24

Beat

by $0.04

Q3'24

Beat

by $0.01

Q2'24

Est.

$-0.35

Q1'24

Beat

by $0.03

The last earnings report on March 13 showed earnings per share of -28 cents, beating the estimate of -31 cents. With 349.76K shares outstanding, the current market capitalization sits at 345.45M.

View a ticker or compare two or three

Compare

ALLO